MedImmune Licenses Technology to Hungary's Omninvest for Influenza Vaccine Production
MedImmune (Gaithersburg, MD) has licensed its proprietary reverse genetics intellectual property to Omninvest, a Hungarian research and manufacturing company, to support the development and construction of new vaccine strains to produce non-live human influenza vaccines.
MedImmune (Gaithersburg, MD) has licensed its proprietary reverse genetics intellectual property to Omninvest, a Hungarian research and manufacturing company, to support the development and construction of new vaccine strains to produce non-live human influenza vaccines. Reverse genetics allows viruses such as influenza to be generated from segments of DNA so that manufacturers do not have to work directly with potentially highly infectious circulating pandemic strains, such as H5N1. This announcement marks the second agreement of this kind that MedImmune signed in the third quarter of 2008.
Most influenza vaccine manufacturing companies and governmental agencies are now using reverse genetics technology in their development of pandemic vaccine candidates. As the owner or exclusive licensee of key patent estates for use of the reverse genetics technology in human influenza vaccines, MedImmune has offered other influenza vaccine manufacturers non-exclusive licenses to these intellectual property estates for use in manufacturing seasonal or pandemic vaccines.
In a first for any influenza vaccine manufacturer, MedImmune applied the reverse genetics process to the development of its seasonal live, attenuated nasal spray influenza vaccine for the 2008–2009 season.
MedImmune release
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
